Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Sep 2022 Results assessing integrated the nAb and sequence data types by assessing neutralizing antibody titers as a correlate of sequence-specific virologically-confirmed dengue separately in the vaccine arm and in the placebo arm, published in the Vaccine.
26 Jun 2021 Results investigating how natural infection-elicited nAbs are related to long-term instantaneous risk of hospitalized dengue from two trials (CYD14 and CYD15) published in the Journal of Infectious Diseases
04 Apr 2021 Results of post-hoc analysis assessing hospitalized and severe VCD cases over the entire six-year follow-up of (two Phase III trials (CYD14 [NCT01373281] and CYD15 [NCT01374516]) and the Phase IIb trial (CYD23/CYD57 [NCT00842530/NCT01983553]) published in the Clinical Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com